M. Desnos-Ollivier, S. Bretagne, Dorothée Raoux, D. Hoinard, F. Dromer, E. Dannaoui (2008)
Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility TestingAntimicrobial Agents and Chemotherapy, 52
E. Kuse, P. Chetchotisakd, C. Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao, J. Sekhon, Antonio Freire, V. Ramasubramanian, I. Demeyer, M. Nucci, A. Leelarasamee, F. Jacobs, J. Decruyenaere, D. Pittet, A. Ullmann, L. Ostrosky-Zeichner, O. Lortholary, S. Koblinger, H. Diekmann-Berndt, O. Cornely (2007)
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trialThe Lancet, 369
M. Baixench, Naji Aoun, M. Desnos-Ollivier, D. Garcia-Hermoso, S. Bretagne, Sandrine Ramires, C. Piketty, E. Dannaoui (2007)
Acquired resistance to echinocandins in Candida albicans: case report and review.The Journal of antimicrobial chemotherapy, 59 6
G. García-Effrón, Samuel Lee, Steven Park, J. Cleary, D. Perlin (2009)
Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β-d-Glucan Synthase: Implication for the Existing Susceptibility BreakpointAntimicrobial Agents and Chemotherapy, 53
N. Wiederhold, J. Grabinski, G. García-Effrón, D. Perlin, Samuel Lee (2008)
Pyrosequencing To Detect Mutations in FKS1 That Confer Reduced Echinocandin Susceptibility in Candida albicansAntimicrobial Agents and Chemotherapy, 52
P. Pappas, C. Rotstein, R. Betts, M. Nucci, D. Talwar, J. Waele, J. Vázquez, B. Dupont, D. Horn, L. Ostrosky-Zeichner, A. Reboli, B. Suh, R. Digumarti, Chunzhang Wu, L. Kovanda, L. Arnold, D. Buell (2007)
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 45 7
Jorge Mora-Duarte, R. Betts, C. Rotstein, A. Colombo, Luis Thompson-Moya, Juanita Smietana, R. Lupinacci, C. Sable, N. Kartsonis, J. Perfect (2002)
Comparison of caspofungin and amphotericin B for invasive candidiasis.The New England journal of medicine, 347 25
P. Pappas, C. Kauffman, D. Andes, D. Benjamin, T. Calandra, J. Edwards, S. Filler, J. Fisher, B. Kullberg, L. Ostrosky-Zeichner, A. Reboli, J. Rex, T. Walsh, J. Sobel (2009)
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 48 5
L. Ostrosky-Zeichner, J. Rex, P. Pappas, R. Hamill, R. Larsen, H. Horowitz, W. Powderly, N. Hyslop, C. Kauffman, J. Cleary, J. Mangino, Jeannette Lee (2003)
Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United StatesAntimicrobial Agents and Chemotherapy, 47
M. Pfaller, S. Messer, L. Boyken, C. Rice, S. Tendolkar, R. Hollis, D. Diekema (2004)
Further Standardization of Broth Microdilution Methodology for In Vitro Susceptibility Testing of Caspofungin against Candida Species by Use of an International Collection of More than 3,000 Clinical IsolatesJournal of Clinical Microbiology, 42
S. Simjee, P. Silley, H. Werling, R. Bywater (2007)
Potential confusion regarding the term 'resistance' in epidemiological surveys.The Journal of antimicrobial chemotherapy, 61 1
F. Odds, M. Motyl, Roberto Andrade, J. Billé, E. Cantón, M. Cuenca‐Estrella, A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. Fothergill, M. Ghannoum, R. Giacobbe, M. Gobernado, R. Handke, M. Laverdière, Wendy Lee-Yang, W. Merz, L. Ostrosky-Zeichner, J. Pemán, S. Perea, J. Perfect, M. Pfaller, L. Proia, J. Rex, M. Rinaldi, J. Rodríguez-Tudela, W. Schell, C. Shields, D. Sutton, P. Verweij, D. Warnock (2004)
Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus SpeciesJournal of Clinical Microbiology, 42
G. García-Effrón, Steven Park, D. Perlin (2008)
Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive BreakpointsAntimicrobial Agents and Chemotherapy, 53
(2007)
Diekmann-Berndt, O. A. Cornely, and the Micafungin Invasive Candidiasis Working Group
G. Thompson, N. Wiederhold, A. Vallor, Nyria Villareal, James Lewis, T. Patterson (2008)
Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata InfectionAntimicrobial Agents and Chemotherapy, 52
N. Kartsonis, John Killar, L. Mixson, C. Hoe, C. Sable, K. Bartizal, M. Motyl (2005)
Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment OutcomeAntimicrobial Agents and Chemotherapy, 49
M. Arendrup, G. Kahlmeter, J. Rodríguez-Tudela, J. Donnelly (2009)
Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target SpeciesAntimicrobial Agents and Chemotherapy, 53
John Turnidge, Gunnar Kahlmeter, Göran Kronvall (2006)
Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 12 5
G. Kahlmeter, Derek Brown (2004)
Harmonization of antimicrobial breakpoints in Europe — Can it be achieved?Clinical Microbiology Newsletter, 26
M. Pfaller, L. Boyken, R. Hollis, J. Kroeger, S. Messer, S. Tendolkar, D. Diekema (2007)
In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global SurveillanceJournal of Clinical Microbiology, 46
M. Pfaller, L. Boyken, R. Hollis, S. Messer, S. Tendolkar, D. Diekema (2005)
In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to FluconazoleJournal of Clinical Microbiology, 43
J. Turnidge, D. Paterson (2007)
Setting and Revising Antibacterial Susceptibility BreakpointsClinical Microbiology Reviews, 20
P. Wayne (2002)
Reference method for broth dilution antifungal susceptibility testing of yeasts, Approved standard-second edition
M. Pfaller, L. Boyken, R. Hollis, S. Messer, S. Tendolkar, D. Diekema (2006)
Global Surveillance of In Vitro Activity of Micafungin against Candida: a Comparison with Caspofungin by CLSI-Recommended MethodsJournal of Clinical Microbiology, 44
G. Kahlmeter, Derek Brown, F. Goldstein, A. Macgowan, J. Mouton, Anders Osterlund, A. Rodloff, M. Steinbakk, P. Urbášková, A. Vatopoulos (2003)
European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria.The Journal of antimicrobial chemotherapy, 52 2
J. Tudela, J. Donnelly, M. Arendrup, S. Arikan, F. Barchiesi, J. Billé, E. Chryssanthou, M. Cuenca‐Estrella, E. Danaoui, D. Denning, W. Fegeler, P. Gaustad, N. Klimko, C. Lass‐Flörl, C. Moore, M. Richardson, A. Schmalreck, J. Stenderup, A. Velegraki, P. Verweij (2008)
EUCAST technical note on fluconazole.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 14 2
G. García-Effrón, D. Kontoyiannis, R. Lewis, D. Perlin (2008)
Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic MalignanciesAntimicrobial Agents and Chemotherapy, 52
P. Murray, E. Baron, J. Jorgensen, M. Landry, M. Pfaller (1975)
Manual of clinical microbiologyMycologia, 67
K. Hazen, S. Howell, P. Murray, E. Baron, J. Jorgensen, M. Landry, M. Pfaller (2006)
Candida, Cryptococcus, and other yeasts of medical importance.
M. Pfaller, L. Boyken, R. Hollis, S. Messer, S. Tendolkar, D. Diekema (2006)
In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global SurveillanceJournal of Clinical Microbiology, 44
M. Pfaller, D. Diekema, L. Ostrosky-Zeichner, J. Rex, B. Alexander, D. Andes, Steven Brown, V. Chaturvedi, M. Ghannoum, C. Knapp, D. Sheehan, T. Walsh (2008)
Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC BreakpointsJournal of Clinical Microbiology, 46
M. Laverdière, R. Lalonde, J. Baril, D. Sheppard, Steven Park, D. Perlin (2006)
Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.The Journal of antimicrobial chemotherapy, 57 4
Journal of Clinical Microbiology – Unpaywall
Published: Nov 19, 2009
Access the full text.
Sign up today, get DeepDyve free for 14 days.